The geographic atrophy (GA) enlargement rate in one eye does not consistently predict the enlargement rate in the fellow eye, ...

OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye ...

Lead candidate, CBT-001 for the treatment of pterygium, a multi-billion-dollar addressable market, is in mid-Phase 3 with ...

India, April 7 -- Dentists spend long hours under focused LED and blue light sources, often without eye protection. This increases their risk of retinal damage, Age-related Macular Degeneration (AMD), ...

Amgen announces positive phase 3 results for subcutaneous Tepezza in adults living with moderate-to-severe active thyroid eye disease: Thousand Oaks, California Wednesday, April 8 ...

In AREDS2, geographic atrophy enlargement rates in fellow eyes showed only modest and variable correlations based on lesion characteristics.

Why it’s Vogue-approved: Powered by TFC8, the brand’s proprietary blend of peptides, amino acids and vitamins, this indulgent ...

Whether you’re perpetually tired or just going through the natural process of getting older, undereye bags are a top skin ...

The debate about AI’s impact is not just about technology; it is also about the gap between how it works and how it appears ...

Ultra Violette specialises in SPF, with no less than ten sunscreen products in its brand arsenal. Supreme screen is the ...

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...